KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 10 years, with Q3 2025 value amounting to $200.2 million.

  • Alnylam Pharmaceuticals' Other Operating Expenses rose 13299.46% to $200.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $517.0 million, marking a year-over-year increase of 6871.62%. This contributed to the annual value of $323.4 million for FY2024, which is 417.65% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Other Operating Expenses is $200.2 million, which was up 13299.46% from $143.0 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Other Operating Expenses high stood at $200.2 million for Q3 2025, and its period low was $31.1 million during Q1 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Operating Expenses had a median value of $66.0 million in 2024 and averaged $71.4 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Other Operating Expenses soared by 13351.38% in 2021 and then crashed by 1955.96% in 2024.
  • Alnylam Pharmaceuticals' Other Operating Expenses (Quarter) stood at $37.7 million in 2021, then soared by 36.11% to $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then rose by 19.75% to $102.8 million in 2024, then soared by 94.67% to $200.2 million in 2025.
  • Its Other Operating Expenses was $200.2 million in Q3 2025, compared to $143.0 million in Q2 2025 and $71.0 million in Q1 2025.